Navigation Links
Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Date:9/3/2014

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO® is a registered trademark of Genzyme Corporation.

Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
2. Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome
3. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
4. VentiRx Pharmaceuticals Provides Corporate and Clinical Update
5. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
6. VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer
7. DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
8. CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years
9. Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytrens Cords At ASSH Annual Meeting
10. TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
11. DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... May 9, 2017  Semler Scientific, Inc. (OTCQB: ... solutions to improve the clinical effectiveness and efficiency ... the first quarter ended March 31, 2017. ... our customers to identify when preventive care options ... events like heart attacks or strokes occur," said ...
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has ... ART laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools ...
(Date:5/23/2017)... ... May 23, 2017 , ... Orbita’s Nathan Treloar will discuss the role ... San Francisco. Titled Connected Health and IoT: Technology Innovators and Disruption , the ... Parks Associates, a market research and consulting firm specializing in emerging consumer technology products ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... Patients who ... to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. ... for a variety of treatments. One or more sedation methods may be recommended based ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., wants to offer ... hand was damaged in a firework accident, so she couldn’t grip a pen properly," ... , He then designed and created a prototype for the HELPEN HAND, a special ...
Breaking Medicine News(10 mins):